News archive

Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.

In this interview, Reshema Kemps-Polanco shares her top career tips, the mindset that drives her, and the quote she still lives by today.

Thierry Diagana, California Sites Head at Novartis, shares the vision for a new research hub that will power future drug discovery.

Maurice W.*, a Medical Science Liaison at Novartis, was shocked to learn he had elevated Lp(a), an inherited risk factor for heart disease.^1,2

At Aspen Ideas Health, Novartis is leading conversations about how to address today’s most pressing healthcare concerns. Learn how we’re launching bold awareness campaigns and unique community partnerships—meeting patients where they are to drive change.

Katy Shusta is helping to rewrite the narrative around hidradenitis suppurativa (HS) – a painful skin condition impacting as many as one in 100 people worldwide.¹  

Learn about the launch of our new state-of-the-art space, built to accelerate innovation from the inside out and provide new solutions for employees, partners and ultimately, our patients.